Patterns and predictors of change in outcome measures in clinical trials in scleroderma: An individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis

Arthritis and Rheumatism

Volumn 64, Issue 10, 2012, Pages 3420-3429

  Merkel, P A ^a,b   Silliman, N P ^c   Clements, P J ^d   Denton, C P ^e   Furst, D E ^d   Mayes, M D ^f   Pope, J E ^g   Polisson, R P ^c   Streisand, J B ^c   Seibold, J R ^h  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BOSTON UNIVERSITY   (United States)

^c GENZYME CORPORATION   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF TEXAS   (United States)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE;

ARTICLE; CLINICAL TRIAL (TOPIC); DATA BASE; DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS; DISEASE DURATION; FORCED VITAL CAPACITY; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HUMAN; INFORMATION PROCESSING; LUNG DIFFUSION CAPACITY; META ANALYSIS; MODIFIED RODNAN SKIN THICKNESS SCORE; MULTICENTER STUDY (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCLERODERMA; SCORING SYSTEM; SYSTEMIC SCLEROSIS;

ADULT; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); SCLERODERMA, DIFFUSE; TREATMENT OUTCOME;

EID: 84863469731     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34427     Document Type: Article

References (24)

1. Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999; 42: 1194-203. (Pubitemid 29268956)
2. Khanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, et al, for the Relaxin Investigators and the Scleroderma Clinical Trials Consortium. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009; 60: 1102-11.
3. Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW, Mayes MD, et al. Recombinant human relaxin in the treatment of scleroderma: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000; 132: 871-9. (Pubitemid 30346849)
4. Black CM, Silman AJ, Herrick AI, Denton CP, Wilson H, Newman J, et al. Interferon-α does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999; 42: 299-305. (Pubitemid 29072847)
5. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44: 1351-8. (Pubitemid 32537533)
6. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, et al, on behalf of the CAT-192 Study Group and the Scleroderma Clinical Trials Consortium. Recombinant human anti- transforming growth factor β1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007; 56: 323-33. (Pubitemid 46106206)
7. Mayes MD, O'Donnell D, Rothfield NF, Csuka ME. Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial. Arthritis Rheum 2004; 50: 553-7. (Pubitemid 38198839)
8. Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, Furst DE. Current status of outcome measure development for clinical trials in systemic sclerosis: report from OMERACT 6. J Rheumatol 2003; 30: 1630-47. (Pubitemid 36835470)
9. Furst DE, Khanna D, Mattucci-Cerinic M, Silman AJ, Merkel PA, Foeldvari I. Scleroderma - developing measures of response. J Rheumatol 2005; 32: 2477-80. (Pubitemid 41780673)
10. Furst D, Khanna D, Matucci-Cerinic M, Clements P, Steen V, Pope J, et al. Systemic sclerosis: continuing progress in developing clinical measures of response. J Rheumatol 2007; 34: 1194-200. (Pubitemid 46774874)
11. Khanna D, Merkel PA. Outcome measures in systemic sclerosis: an update on instruments and current research. Curr Rheumatol Rep 2007; 9: 151-7. (Pubitemid 46932722)
12. Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000; 43: 2445-54.
13. Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001; 44: 2828-35. (Pubitemid 34016202)
14. Poole JL, Steen VD. The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 1991; 4: 27-31.
15. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997; 40: 1984-91. (Pubitemid 27494658)
16. Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, et al. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum 2001; 44: 653-61. (Pubitemid 32234624)
17. Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al, for the Scleroderma Clinical Trials Consortium. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002;46: 2410-20.
18. Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005; 32: 832-40. (Pubitemid 40676492)
19. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
20. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982; 9: 789-93.
21. Furst DE, Clements PJ, Harris R, Ross M, Levy J, Paulus HE. Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine. Ann Rheum Dis 1979; 38: 356-61. (Pubitemid 9255311)
22. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-66.
23. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177: 1248-54. (Pubitemid 351860934)
24. Khanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis 2008; 67: 703-9. (Pubitemid 351571937)